Letermovir vs Valganciclovir in CMV High Risk Liver Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract A076; Pres time: Jun 20, 2026; 05:45 PM - 06:45 PM; Location: Exhibit Hall; "In an early single center experience, LTV was associated with significantly less cytopenias requiring medication adjustment. While there was a higher rate of CMV DNAemia at 6 months with LTV compared to VGC prophylaxis, these cases were uncomplicated. Longer-term study with a larger, more homogenous population is needed to assess if LTV is non-inferior to VGC in safety and efficacy."
Clinical • Hematological Disorders • Leukopenia • Neutropenia • Transplantation
|
|
J. Dann; J. Geyston; T. Parpia; B. Wentworth
|